Moreover, in vitro and animal studies of the tumor-promoting effects from different ALK fusion variants and TP53 mutations in ALK+ disease will be instrumental for deeper mechanistic insights towards uncovering of therapeutic susceptibilities and new drug development. This evidence concerns the gene ALK and neoplasm.